May 22, 2012

Scientist Develops Blood Test to Predict Chances of Dementia

Scientist Develops Blood Test to Predict Chances of Dementia

Article by Mediconews123









Alzheimer?s, frontal lobe dementia (FTD) is the form of dementia that occurs most frequently in patients younger than 65. In FTD, the disease process starts in the frontal lobe where large numbers of brain cells begin to die off.

The frontal lobe is the foremost part of the brain and constitutes about 30% of the brain. It?s involved in regulating behavior, movement and mood, and it?s responsible for cognitive functions such as language.

The first clinical signs of FTD are changes in behavior and personality, and then, in a later stage of the disease, the loss of memory functions.

Previous research has shown that there is a genetic defect in chromosome 17 in a large percentage of the families with FTD. There are two genes in chromosome 17 that, if a defect occurs, cause a hereditable form of FTD.

In 1998, defects were found in the gene for the tau protein, a substance that appears in the protein clots in the brains of FTD and Alzheimer?s patients. In 2006, researchers discovered hereditable defects in the gene for the progranulin protein. They predicted that people with these hereditable defects produce only half of the normal amount of progranulin.

This has been confirmed by the research team, who have shown that a shortage of this growth factor leads to the dying off of brain cells in the frontal lobe and in this way causes FTD. New results indicate that progranulin also plays a role in the death of brain cells in other diseases of the brain, such as Alzheimer?s and Amyotrophic Lateral Sclerosis.

On the basis of their research, Kristel Sleegers, a scientist from the research team, has developed a test for measuring the quantity of progranulin in the blood in a simple way. This test enables one to determine whether someone has an increased risk of FTD due to a shortage of progranulin long before symptoms appear.

The blood test can be used on a large scale and is much more simple and user-friendly than the current genetic tests. This finding also offers prospects for the early detection of FTD caused by a shortage of progranulin.

Further scientific research is needed to determine how a shortage of progranulin can be restored to normal.




About the Author

Written by

Medical News | Cancer

News

: mediconews.com

Dental News : mediconews.com










Frontotemporal dementia (FTD) “Planning for Hope” documentary film

Planning for Hope will be a 1-hour documentary featuring the stories of patients in different stages of battling Frontotemporal dementia (FTD), a commonly misdiagnosed disease that is second in prevalence to Alzheimer’s. The documentary focuses on educating both healthcare professionals and the general public about recognizing and treating FTD. Donations are needed to help complete the final stages of film production and cover distribution and promotion expenses. Your tax-deductible gift will help make a difference for future generations, and all contributions will be gratefully acknowledged in the film credits. Visit ftdtheotherdementia.com
Video Rating: 5 / 5